CALGARY, Alberta, April 30, 2019 (GLOBE NEWSWIRE) -- FluroTech Ltd. (TSX-V: TEST) (OTCQB: FLURF), (“FluroTech” or the “Company”) is pleased to announce the appointment of Duane Sniezek as the full-time Director of Science and Technology. Duane will be hands-on in leading enhancements of the CompleTest™.
“The continuing commercialization of the CompleTest™ is our number one priority,” stated Danny Dalla-Longa. “Duane has demonstrated his ability to bring new technologies to market and will head the Company’s development team.”
“Great science makes great products! I look forward to leveraging the science and expanding the core technology that has been created by the team at FluroTech into new and innovative products for the cannabis industry. Amazing things are possible with a knowledgeable and innovative science and engineering team like the one at FluroTech,” commented Duane. “In this emerging market there is a great opportunity for fast, affordable, accurate and easy to use test and measurement instruments. FluroTech is taking the lead and I am excited to use my background and experience to help to accelerate products into the market.”
Duane Sniezek is the CEO of Terecel Inc., a technology management company focused on driving business results from technology. Duane has a proven executive management track record starting and running 12 private and public companies. With over 30 years of technology strategy, management, product development and commercialization experience, he has a successful track record of launching new products to market. Duane holds a B.Sc. in Electrical Engineering and a B.Sc. in Computer Science from the University of Saskatchewan, and a Diploma in Electronics Engineering Technology from the Southern Alberta Institute of Technology.
About FluroTech (TSX-V: TEST) (OTCQB: FLURF)
FluroTech is a technology and marketing company whose core business is focused on the commercialization of new technologies in the cannabis industry. FluroTech’s proprietary spectroscopy-based technology allows for the testing and identification of organic and inorganic compounds contained within biological samples. Using the technology that was developed at the University of Calgary, FluroTech has developed a two-part solution comprising an instrument called the CompleTest™ and consumable testing kits.
To learn more, visit www.FluroTech.com.
Contact Information
Danny Dalla-Longa
Chief Executive Officer
403.680.0644
danny@flurotech.com
FluroTech Ltd.
Alistair Ross Technology Centre
Suite 111, 3553-31 Street NW
Calgary, AB T2L 2K7
info@flurotech.com
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or the securities laws of any state and may not be offered or sold within the United States or to or for the benefit or account of U.S. persons, absent such registration or an applicable exemption from such registration requirements.
Cautionary Statement Regarding Forward-Looking Information
This news release contains "forward-looking information" within the meaning of Canadian securities legislation. Forward-looking information generally refers to information about an issuer’s business, capital, or operations that is prospective in nature, and includes future-oriented financial information about the issuer’s prospective financial performance or financial position. The forward-looking information in this news release includes disclosure about continuing commercialization of the CompleTest™, opportunity for fast, affordable, accurate and easy to use test and measurement instruments and FluroTech taking the in the market.
The Company made certain material assumptions, including but not limited to prevailing market conditions and general business, economic, competitive, political and social uncertainties, the need and demand for the CompleTest™ technology in the cannabis and hemp industry, to develop the forward-looking information in this news release. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
Actual results may vary from the forward-looking information in this news release due to certain material risk factors. These risk factors include, but are not limited to, adverse market conditions and regulatory and other risks associated with the cannabis and hemp industries in general, users of the Company’s the CompleTest™ failing to achieve the anticipated benefits of the product, competition from other developers of similar technology, failure to reach commercialization of the technology and failure for the products anticipated market to develop. The Company cautions that the foregoing list of material risk factors and assumptions is not exhaustive.
The Company assumes no obligation to update or revise the forward-looking information in this news release, unless it is required to do so under Canadian securities legislation.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release.